# Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: PCVX
Company: Vaxcyte
Source: Vaxcyte
Published: 2026-05-06 20:05 EST
Original Source URL: https://investors.vaxcyte.com
## Summary

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected

## Article Body
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected
## Recent Company News
- 2026-06-02 20:05 EST — [Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults](https://biopharmsignal.com/news/PCVX/vaxcyte-doses-first-participant-in-phase-1-study-evaluating-vax-a1-for-the-prevention-of-disease-caused-by-group-a-streptococcus-in-healthy-adults) — Source: Vaxcyte
- 2026-05-06 20:05 EST — [Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Vaxcyte
- 2026-04-07 20:05 EST — [Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/PCVX/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Vaxcyte
- 2026-03-23 12:30 EST — [Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults](https://biopharmsignal.com/news/PCVX/vaxcyte-completes-enrollment-of-opus-1-and-opus-2-phase-3-trials-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumonia-in-adults) — Source: Vaxcyte
- 2026-03-18 23:34 EST — [Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate](https://biopharmsignal.com/news/PCVX/positive-vax-31-phase-1-2-adult-data-published-in-the-lancet-infectious-diseases-highlight-best-in-class-potential-of-vaxcyte-s-31-valent-pneumococcal-conjugate-vaccine-pcv-candidate) — Source: Vaxcyte
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)